Teva Gets Generic Drugmakers’ Backing in Bid to Redo Label Case

Generic drugmakers are lining up behind Teva Pharmaceuticals to tear down a product label ruling they claim jeopardizes their ability to get low-cost drugs to market as the Federal Circuit weighs whether to rehear the case for the third time.

A divided U.S. Court of Appeals for the Federal Circuit panel has twice ruled that Teva’s label on a copycat version of GlaxoSmithKline Plc’s Coreg heart drug led doctors to prescribe the generic for an infringing use. The outcome saddles Teva with a $235 million penalty, and case watchers say the latest ruling discourages generic producers from using routine labeling ...